Drug-induced Sweet's syndrome: A case/non-case study in the French pharmacovigilance database.
Sweet's syndrome
adverse drug reaction
case/non-case study
drug safety
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
09 Aug 2023
09 Aug 2023
Historique:
revised:
10
07
2023
received:
20
01
2023
accepted:
26
07
2023
pubmed:
9
8
2023
medline:
9
8
2023
entrez:
9
8
2023
Statut:
aheadofprint
Résumé
Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration. To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non-case study on reports of 'acute febrile neutrophilic dermatosis' registered in the French pharmacovigilance database. Reporting odds ratio (ROR) with its 95% confidence interval were calculated. Amongthe 994 789 reports recorded in the database, 136 were Sweet's syndrome, of which 50.7% were men and the median age was 59 years (range 15-91). A total of 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics and 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet's syndrome was 15 days (range 1-1095). The highest RORs were observed with bortezomib (74.04 [40.8-134.2]), azacitidine (72.14 [29.4-176.9]), perfilgrastim (67.05 [21.2-211.6]), azathioprine (55.46 [34.8-88.4]) and bendamustine (35.84 [11.4-112.8]). Pharmacovigilance signals have been observed between the occurrence of Sweet's syndrome and colony-stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and should be encouraged to report any case of drug-induced Sweet's syndrome.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76(8-9):349-356. doi:10.1111/j.1365-2133.1964.tb14541.x
Cohen PR. Sweet's syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2(1):34. doi:10.1186/1750-1172-2-34
Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761-778. doi:10.1046/j.1365-4362.2003.01891.x
Heath MS, Ortega-Loayza AG. Insights into the pathogenesis of Sweet's syndrome. Front Immunol. 2019;10:414. doi:10.3389/fimmu.2019.00414
Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis. 1986;37(3):167-174.
Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996;34(5 Pt 2):918-923. doi:10.1016/S0190-9622(96)90080-8
Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet syndrome: a review and update. Actas Dermosifiliogr. 2016;107(5):369-378. doi:10.1016/j.ad.2015.12.001
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905-908. doi:10.1111/j.1365-2125.2011.04037.x
Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. French pharmacovigilance database system: examples of utilisation. Therapie. 1995;50(6):557-562. doi:10.1016/j.therap.2019.09.004
Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225-232. doi:10.1016/j.therap.2019.01.006
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109-117. doi:10.2165/00002018-199920020-00002
Sáez M, García-Bustínduy M, Noda A, et al. Drug-induced Sweet's syndrome. J Eur Acad Dermatol Venereol. 2004;18(2):233. doi:10.1111/j.1468-3083.2004.00866.x
Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557-564. doi:10.1016/j.jaad.2013.06.023
Thompson DF, Montarella KE. Drug-induced Sweet's syndrome. Ann Pharmacother. 2007;41(5):802-811. doi:10.1345/aph.1H563
Kim MJ, Choe YH. EPONYM. Sweet syndrome. Eur J Pediatr. 2010;169(12):1439-1444. doi:10.1007/s00431-010-1201-z
Neely G, Fajre X, Cabrera R, Castro A. Lamotrigine-induced Sweet syndrome: possible new drug association. JAAD Case Rep. 2020;6(10):1009-1011. doi:10.1016/j.jdcr.2020.07.043
Dev T, Dudani P, Bhari N. Azacytidine induced localized Sweets syndrome in myelodysplastic syndrome. Dermatol Ther. 2021;34(2):e14754. doi:10.1111/dth.14754
Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor [published correction appears in J Clin Oncol. 2008 Nov 20;26(33):5493]. J Clin Oncol. 2008;26(26):4355-4356. doi:10.1200/JCO.2008.16.2933
Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995;33(3):393-412. doi:10.1016/0190-9622(95)91382-3
Draper BK, Robbins JB, Stricklin GP. Bullous Sweet's syndrome in congenital neutropenia: association with pegfilgrastim. J Am Acad Dermatol. 2005;52(5):901-905. doi:10.1016/j.jaad.2004.12.028
Choonhakarn C, Chaowattanapanit S. Azathioprine-induced Sweet's syndrome and published work review. J Dermatol. 2013;40(4):267-271. doi:10.1111/1346-8138.12081
McNally A, Ibbetson J, Sidhu S. Azathioprine-induced Sweet's syndrome: a case series and review of the literature. Australas J Dermatol. 2017;58(1):53-57. doi:10.1111/ajd.12383
Patel AV, Jotwani PM, Sultan KS. Azathioprine-induced Sweet syndrome treated with infliximab. Am J Ther. 2019;26(5):e616-e617. doi:10.1097/MJT.0000000000000820
Knoops L, Jacquemain A, Tennstedt D, Theate I, Ferrant A, van den Neste E. Bortezomib-induced Sweet syndrome. Br J Haematol. 2005;131(2):142. doi:10.1111/j.1365-2141.2005.05636.x
Zobniw CM, Saad SA, Kostoff D, Barthel BG. Bortezomib-induced Sweet's syndrome confirmed by rechallenge. Pharmacotherapy. 2014;34(4):e18-e21. doi:10.1002/phar.1383
Tiwari SM, Caccetta T, Kumarasinghe SP, Harvey N. Azacitidine-induced Sweet syndrome: two unusual clinical presentations. Australas J Dermatol. 2018;59(3):e224-e225. doi:10.1111/ajd.12727
Trickett HB, Cumpston A, Craig M. Azacitidine-associated Sweet's syndrome. Am J Health Syst Pharm. 2012;69(10):869-871. doi:10.2146/ajhp110523
Yang JJ, Maloney NJ, Nguyen KA, Worswick S, Smogorzewski J, Bach DQ. Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: a review. Dermatol Ther. 2021;34(1):e14461. doi:10.1111/dth.14461
Mohamed A. Enasidenib-induced Sweet syndrome with differentiation syndrome. Clin Case Rep. 2021;9(5):e04099. doi:10.1002/ccr3.4099
Anzalone CL, Cohen PR. Acute febrile neutrophilic dermatosis (Sweet's syndrome). Curr Opin Hematol. 2013;20(1):26-35. doi:10.1097/MOH.0b013e32835ad132
Ginarte M, García Doval I, Toribio J. Sweet's syndrome: a study of 16 cases. Med Clin (Barc). 1997;109(15):588-591.
Gilmour E, Chalmers RJ, Rowlands DJ. Drug-induced Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine. Br J Dermatol. 1995;133(3):490-491. doi:10.1111/j.1365-2133.1995.tb02686.x
Kazlouskaya V, Junkins-Hopkins JM, Wu KN, Itenberg SJ. Sweet syndrome caused by oral contraceptives. Int J Dermatol. 2015;54(5):e189-e191. doi:10.1111/ijd.12759
Gkrouzman E, Chirch L, Lakshminarayanan S. Drug-induced Sweet syndrome in a man with sarcoidosis: are there any common mechanisms of pathogenesis? J Clin Rheumatol. 2019;25(7):e122-e126. doi:10.1097/RHU.0000000000000730
Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628-2638. doi:10.1056/NEJMoa2026834
Himmelmann A, Brücker R. The VEXAS syndrome: uncontrolled inflammation and macrocytic anaemia in a 77-year-old male patient. Eur J Case Rep Intern Med. 2021;8(4):002484. doi:10.12890/2021_002484
Matsubara A, Tsuchida N, Sakurai M, et al. A case of VEXAS syndrome with Sweet's disease and pulmonary involvement. J Dermatol. 2022;49(5):e177-e178. doi:10.1111/1346-8138.16311
Nofal A, Abdelmaksoud A, Amer H, et al. Sweet's syndrome: diagnostic criteria revisited. J Dtsch Dermatol Ges. 2017;15(11):1081-1088. doi:10.1111/ddg.13350
Kalai C, Brand R, Yu L. Minocycline-induced Sweet syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 2012;67(6):e289-e291. doi:10.1016/j.jaad.2012.07.005
Ratzinger G, Burgdorf W, Zelger BG, Zelger B. Acute febrile neutrophilic dermatosis: a histopathologic study of 31 cases with review of literature. Am J Dermatopathol. 2007;29(2):125-133. doi:10.1097/01.dad.0000249887.59810.76
Amouri M, Masmoudi A, Ammar M, et al. Sweet's syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol. 2016;55(9):1033-1039. doi:10.1111/ijd.13232
Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in Sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients. Arch Dermatol. 2002;138(3):345-349. doi:10.1001/archderm.138.3.345
Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47(3):329-331. doi:10.1046/j.1365-2125.1999.00881.x
Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288(13):1588. doi:10.1001/jama.288.13.1588